Tonghua Dongbao Pharmaceutical's EPS and revenue saw a dip, but share prices still rose, indicating that investors might be considering factors other than EPS. The annual shareholder return was 38%, primarily from dividends, significantly outperforming the 1.1% TSR loss over five years.